Product
BLU-222
Name
BLU-222
1 clinical trial
9 indications
5 posters
Indication
CancerIndication
HR+ Breast CancerIndication
CCNE1 AmplificationIndication
Breast CancerIndication
Ovarian CancerIndication
Endometrial CancerIndication
Stomach CancerIndication
Esophageal adenocarcinomaIndication
CarcinosarcomaClinical trial
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-11-30